Drug Profile
AMG 562
Alternative Names: AMG-562Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amgen
- Class Antibodies; Antineoplastics; Bispecific antibodies
- Mechanism of Action CD19 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
Most Recent Events
- 28 Oct 2020 Discontinued - Phase-I for Diffuse large B cell lymphoma (Metastatic disease, Second-line therapy or greater) in Germany, Canada (Parenteral)
- 28 Oct 2020 Discontinued - Phase-I for Follicular lymphoma (Metastatic disease, Second-line therapy or greater) in Germany, Canada (Parenteral)
- 28 Oct 2020 Discontinued - Phase-I for Mantle-cell lymphoma (Metastatic disease, Second-line therapy or greater) in Germany, Canada (Parenteral)